| Name | Title | Contact Details |
|---|
Novacam Technologies, Inc. is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Adventus Group is a Freeport, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Joule has pioneered a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Free of feedstock constraints and complex processing, this platform can achieve unrivaled scalability, volumes and costs without the use of any agricultural land, fresh water or crops. Unlike products derived with complexity from petroleum or biomass, Joule Sunflow® products are produced in a direct, continuous process from abundant resources. The novel CO2-to-liquids conversion requires only sunlight, non-potable water and engineered bacteria that function as living catalysts to produce specific products, including ethanol and hydrocarbon fuels that are inherently compatible with existing infrastructure. Joule’s highly efficient process and production system are well suited for deployment around the world, unhindered by land or resource constraints. This uniquely modular system can achieve replicable productivity, whether installed across 100 or 1,000 acres, mitigating scale-up risks and ensuring stability of supply. At full-scale commercialization in ideal locations, the company ultimately targets 25,000 US gallons of Joule Sunflow®-E (solar ethanol) or 15,000 US gallons of Joule Sunflow®-D (solar diesel) per acre annually, for approximately $1.20/US gallon ($50/barrel). Joule has successfully pilot-tested its platform for over two years, initiated demonstration-scale operations, and assembled a specialized team to lay the groundwork for commercial deployment. The company is moving rapidly to commercialize Joule Sunflow-E, with Joule Sunflow-D and additional hydrocarbon fuels to follow. Joule is privately held and has raised approximately $200 million in funding to date. The company was founded within Flagship VentureLabs™, and operates out of Bedford, Massachusetts and The Hague, The Netherlands, with production operations in Hobbs, New Mexico.
CPS Instruments is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our mission is clear: To build a breakthrough oncology company creating neoantigen-based therapeutics that significantly improve the lives of patients. Neon Therapeutics is a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, we believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy that will drive a strong risk-benefit profile to dramatically improve patient outcomes. We pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies. Our platform seeks to identify and harness the most therapeutically relevant neoantigens present within each patient`s tumor, and comprises three key elements that form an iterative feedback loop: our RECONTMBioinformatics Engine; our deep capabilities in peptide chemistry and manufacturing; and our combined NEON-STIMTM T cell biology and immune-monitoring expertise. Our company builds on more than a decade of pioneering work by our world-class scientific founders across multiple leading global institutions including the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, MD Anderson Cancer Center, the Netherlands Cancer Institute and Washington University in St. Louis. Our founders were central to the development of both the fields of immuno-oncology and neoantigens and have published a number of seminal papers outlining the importance of neoantigens as critical immune targets for treating cancer.